Skip to main content

Hormonal Assessment

Hormonal assessment helps evaluate erectile dysfunction, reduced libido, suspected hypogonadism and selected fertility problems. A broad hormone panel is not a routine prerequisite for IPP or AUS implantation. Baseline hematocrit and prostate assessment become relevant when testosterone treatment is being considered. PSA requires attention to medications and hormone exposure, particularly 5-alpha-reductase inhibitors and feminizing therapy.[1][2][4]

Testosterone & Gonadotropin Panel​

AUA uses total testosterone <300 ng/dL on two separate early-morning measurements, together with compatible symptoms or signs. The Endocrine Society recommends morning fasting sampling; AUA does not insist on fasting. Avoid diagnosing from a single sample during acute illness, and use an accurate assay and clinically appropriate timing.[1][12]

Indications in the Reconstructive Population​

ScenarioRationale
Erectile dysfunction (any etiology)Testosterone is part of the AUA-recommended initial ED workup; correction may improve PDE5i responsiveness
Prostate-cancer survivorshipConfirm deficiency if suspected, then discuss treatment with the oncology team; evidence is insufficient to quantify the risk–benefit of TRT after prostate cancer. An undetectable PSA alone does not settle candidacy.[1]
Post-radiation, post-pelvic-trauma, spinal-cord injuryHigher prevalence of secondary hypogonadism; affects rehabilitation goals
Pre-IPP counselingAddress libido, endocrine symptoms and expectations; routine pretreatment with testosterone has not been established as a way to improve every implant outcome
Decreased libido / fatigue / loss of morning erectionsStandard symptom cluster for AUA evaluation

Conditions Warranting Testosterone Measurement Even Without Symptoms​

Per the AUA 2018 Testosterone Deficiency Guideline, clinicians may consider testing in several associated conditions even without classic symptoms; this is a case-finding decision rather than automatic treatment of an isolated low value:[1]

  • Unexplained anemia
  • Bone-density loss / osteoporosis
  • Diabetes mellitus
  • Chemotherapy exposure
  • Testicular radiation
  • HIV / AIDS
  • Chronic narcotic / opioid use
  • Infertility
  • Pituitary dysfunction
  • Chronic corticosteroid use

Consider reversible contributors, reproductive goals and whether the result will change care. Association with a comorbidity does not itself establish a testosterone-treatment indication.[6]

Reflex Labs When Total T Is Low​

When total T returns <300 ng/dL on confirmatory testing, the next-step labs distinguish primary from secondary hypogonadism and identify treatable secondary causes:[1][5][6]

  • LH — elevated in primary (testicular) hypogonadism; low/normal in secondary (hypothalamic-pituitary)
  • FSH — adds infertility-axis information; elevated FSH with normal LH suggests Sertoli-cell dysfunction
  • Prolactin — order if LH is low/normal; prolactinoma is a treatable cause of secondary hypogonadism
  • Estradiol — order if gynecomastia is present or aromatase-inhibitor therapy is being considered
  • SHBG and free testosterone — useful when total T is borderline or altered SHBG is suspected. Low SHBG (for example with obesity or type 2 diabetes) can lower total T while free T remains normal. High SHBG (for example with aging, HIV or estrogen exposure) can leave total T normal/high despite low free T. Use equilibrium dialysis or a validated calculation from total T, SHBG and albumin; direct analog free-T immunoassays are unreliable.[12]

Hematocrit — Baseline AND On-Therapy​

AUA recommends baseline hemoglobin/hematocrit and follow-up during treatment:[1]

  • Baseline Hct >50%: withhold initiation while investigating the cause.
  • On-treatment Hct ≥54%: intervene. With high testosterone levels, dose adjustment is generally first; other patterns may require free-T/SHBG assessment and hematology input. Phlebotomy is not an automatic substitute for investigating the cause.
  • During stable treatment, check hematocrit every 6–12 months or sooner according to prior values and clinical circumstances; early follow-up depends on formulation and the treatment plan.

The TRAVERSE trial (n=5,246, 2023 NEJM) reframed the cardiovascular conversation around TRT — confirming non-inferiority for major adverse cardiovascular events but identifying signals for atrial fibrillation, pulmonary embolism, and acute kidney injury that should be discussed in shared decision-making.[7]

PSA in the Reconstructive Practice​

Use shared decision-making and individual risk. The AUA/SUO screening framework allows a baseline PSA at 45–50 years, earlier assessment at 40–45 for increased risk, and regular screening at 50–69 with individualized intervals. These are distinct recommendations, not one universal 45–69 rule. The 2026 amendment updates imaging, biomarkers, biopsy techniques and ASAP management; a PSA value alone should not dictate biopsy.[3][13]

When We Order PSA​

  • Pre-TRT baseline in men ≥40 — required by AUA 2018 before initiating testosterone therapy[1]
  • On-TRT surveillance — agree on prostate monitoring before treatment, then use an age-, risk- and history-appropriate schedule; TRT does not create one universal lifelong annual PSA schedule[1][12]
  • Post-radical prostatectomy biochemical-recurrence surveillance — PSA is the primary tool; the threshold for biochemical recurrence is ≥0.2 ng/mL confirmed
  • Age/risk-appropriate screening or cancer follow-up, including when relevant to prosthetic counseling; avoid a PSA panel solely because an implant is planned

Reconstruction-Specific Interpretation Caveats​

This is where standard reference ranges fail and the reconstructive surgeon must apply specialty-specific corrections.

5-Alpha-Reductase Inhibitors​

5-ARIs suppress PSA. For finasteride 5 mg, labeling describes an approximately 50% reduction within six months, establishing a new baseline after at least six months, and doubling an isolated value for comparison with untreated reference ranges. Any confirmed rise from the on-treatment nadir merits evaluation, including adherence and other causes, even if the absolute value is within an untreated reference range.[14]

The doubling rule is an approximation affected by duration and individual response. Marks et al. was a review, not a VA cohort validating universal percentage-response bands. It proposed a ≥0.3 ng/mL rise from nadir as an alternative trigger in dutasteride-treated men (71% sensitivity, 60% specificity); this is not a mandate for immediate biopsy after any single 0.3 rise.[9]

The VA cohort of 80,875 men with prostate cancer associated prior 5-ARI use with delayed diagnosis and worse outcomes. This observational finding reinforces the importance of accounting for PSA suppression; it does not prove the drug itself causes aggressive cancer.[10] See 5-Alpha-Reductase Inhibitors.

Gender-Affirming Estrogen Therapy​

Estrogen-based GAHT and/or orchidectomy can markedly lower PSA in people who retain a prostate. No validated PSA screening or biopsy threshold has been established for this population; neither 4.0 ng/mL nor an invented 0.1 ng/mL cutoff should provide automatic reassurance or trigger biopsy.[4][11]

Hall et al.'s 2025 systematic review included four studies, 290 participants, and found insufficient evidence to recommend clinical thresholds. Consider symptoms, hereditary risk, hormone exposure and confirmed trends relative to an appropriate on-treatment baseline. The pre-estrogen baseline is not interchangeable with the suppressed on-treatment baseline. Discuss testing and uncertainty individually; case reports cannot establish a comparative rate of aggressive cancer.[11] See Gender-Affirming Hormone Therapy.

Transient Elevations​

Repeat a newly elevated screening PSA before proceeding to biomarkers, MRI or biopsy, with timing adjusted for recent retention, infection, catheterization or instrumentation. DRE does not usually require a delay; recent biopsy and substantial prostatic manipulation differ from uncomplicated cystoscopy. A symptomatic infection warrants treatment, but antibiotics should not be given merely to lower an otherwise unexplained PSA.[3]

Endocrine Evaluation in Male Infertility​

Evaluate both partners and interpret semen analysis with history and examination. AUA/ASRM recommends FSH and testosterone in infertile men with sexual/endocrine symptoms, oligozoospermia, azoospermia or atrophic testes; LH and prolactin follow the hormonal pattern rather than forming a universal four-test panel.[8][15]

The 2024 AUA/ASRM amendment separates genetic-testing thresholds. In primary infertility with elevated FSH, testicular atrophy or other evidence of impaired production:

  • Karyotype: azoospermia or sperm concentration <5 million/mL.
  • Y-chromosome microdeletions: azoospermia or concentration ≤1 million/mL.

Do not apply these production-failure criteria automatically to obstructive azoospermia. Suspected congenital absence of the vas deferens or idiopathic obstruction calls for a different genetic evaluation. Exogenous testosterone suppresses spermatogenesis and should not be prescribed to a man pursuing current or future fertility without specialist consideration of alternatives.[15]

See Also​

References​

1. Mulhall JP, Trost LW, Brannigan RE, et al. "Evaluation and management of testosterone deficiency: AUA guideline." J Urol. 2018;200(2):423-432. doi:10.1016/j.juro.2018.03.115

2. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004

3. Wei JT, Barocas D, Carlsson S, et al. "Early detection of prostate cancer: AUA/SUO guideline part I — prostate cancer screening." J Urol. 2023;210(1):46-53. doi:10.1097/JU.0000000000003491

4. Nik-Ahd F, Jarjour A, Figueiredo J, et al. "Prostate-specific antigen screening in transgender patients." Eur Urol. 2023;83(1):48-54. doi:10.1016/j.eururo.2022.09.007

5. Heidelbaugh JJ, Belakovskiy A. "Testosterone deficiency in adult men: evaluation and management." Am Fam Physician. 2024;109(6):543-549. https://www.aafp.org/pubs/afp/issues/2024/0600/testosterone-deficiency.html

6. De Silva NL, Papanikolaou N, Grossmann M, et al. "Male hypogonadism: pathogenesis, diagnosis, and management." Lancet Diabetes Endocrinol. 2024;12(10):761-774. doi:10.1016/S2213-8587(24)00199-2

7. Lincoff AM, Bhasin S, Flevaris P, et al. "Cardiovascular safety of testosterone-replacement therapy (TRAVERSE)." N Engl J Med. 2023;389(2):107-117. doi:10.1056/NEJMoa2215025

8. Agarwal A, Baskaran S, Parekh N, et al. "Male infertility." Lancet. 2021;397(10271):319-333. doi:10.1016/S0140-6736(20)32667-2

9. Marks LS, Andriole GL, Fitzpatrick JM, et al. "The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations." J Urol. 2006;176(3):868-874. doi:10.1016/j.juro.2006.04.024

10. Sarkar RR, Parsons JK, Bryant AK, et al. "Association of treatment with 5α-reductase inhibitors with time to diagnosis and mortality in prostate cancer." JAMA Intern Med. 2019;179(6):812-819. doi:10.1001/jamainternmed.2019.0280

11. Hall R, Ball R, Bancroft E, Eeles R, Berner AM. "Prostate-specific antigen reference intervals in the gender-diverse population: a systematic review." BJU Int. 2025. doi:10.1111/bju.16825

12. Bhasin S, Brito JP, Cunningham GR, et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2018;103:1715–1744. doi:10.1210/jc.2018-00229.

13. Lin DW, Carlsson S, Filson CP, et al. "Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026)." J Urol. 2026;215:491–501. doi:10.1097/JU.0000000000004995.

14. Finasteride 5 mg tablets. Prescribing information, section 5.1: Effects on PSA. DailyMed.

15. AUA/ASRM. Diagnosis and Treatment of Infertility in Men (2020; amended 2024). Full guideline.